A Study to Test the Design, Functionality, and Ergonomic Features of the Autoinjector

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

68 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-12-31

Study Completion Date

2008-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to evaluate how well the autoinjector works in a group of people who are likely to use the autoinjector for injecting their medicine in the future. However, no active medicine is given by the autoinjector.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Usability of an AI for M923 in Subjects With Moderate to Severe RA

NCT02722044

Rheumatoid Arthritis

COMPLETED PHASE3

The Usability and Injection Time of the Physiolis Syringe and Autoinjector in Rheumatoid Arthritis Patients

NCT01163617

Rheumatoid Arthritis

COMPLETED PHASE2

Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe

NCT02636907

Arthritis, Rheumatoid

COMPLETED PHASE2

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis

NCT04109976

Psoriatic Arthritis

COMPLETED PHASE3

An Multicentre Clinical Study to Evaluate the Usability and Safety of the Autoinjector and Pre-filled Syringe of SB4 in Subjects With Rheumatoid Arthritis

NCT03193957

Rheumatoid Arthritis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This device (called an autoinjector) automatically injects medicine under the skin with a sterile needle, and is similar to other types of autoinjectors currently being used for this purpose. This trial has been designed to make sure that people, who are likely to use this device, are able to self-inject and understand the training material. A total of 68 subjects took part in the study. About half (30 patients) will have either Rheumatoid Arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS) and the other half will have psoriasis (a type of skin disease), since this device will be used by patients with one of these diseases to inject their medication. The study is designed to have each patient complete 2 self-injections with the autoinjector in 2 different sites-one in the front of the thigh and one in the abdomen 2 inches away from the navel. The order of the first injection location is decided by randomization. The patient will have an equal chance of having the thigh or the abdomen as the first injection. The study staff will assess the subject's safety prior to the patient leaving the clinic. Two prefilled, 1mL placebo autoinjectors for subcutaneous injection

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis Psoriatic Arthritis Ankylosing Spondylitis Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Injection Site: First Thigh Then Abdomen

Participants will self inject subcutaneously placebo using auto injector at thigh followed by self injection of placebo subcutaneously at abdomen on Day 1.

Group Type EXPERIMENTAL

Pre-filled Auto-injector Containing Placebo

Intervention Type DEVICE

Participants will self-inject placebo subcutaneously at thigh and abdomen.

Injection Site: First Abdomen then Thigh

Participants will self inject subcutaneously placebo using auto injector at abdomen followed by self injection of placebo subcutaneously at thigh on Day 1.

Group Type EXPERIMENTAL

Pre-filled Auto-injector Containing Placebo

Intervention Type DEVICE

Participants will self-inject placebo subcutaneously at thigh and abdomen.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pre-filled Auto-injector Containing Placebo

Participants will self-inject placebo subcutaneously at thigh and abdomen.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have the capacity to understand and sign an informed consent form
* Have one of the following diagnoses: rheumatoid arthritis/psoriatic arthritis/ankylosing spondylitis, or psoriasis
* Be willing and able to self-inject

Exclusion Criteria

* Have a recent history of (within 6 months prior to study entry) or current diagnosis of a major bleeding or coagulation disorder
* Have a prior history of a inability to use an autoinjector
* Have an allergy to latex or any component of the autoinjector
* Female participants who are pregnant
* Are unwilling to complete the study assessments

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No